Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed DehydraTECH™, an oral digestion technology believed to improve the absorption rates of nicotine, non-steroid anti-inflammatory drugs (NSAIDs), vitamins and cannabinoids by as much as five to ten times the normal rate. The time of onset is also reduced, and effects are felt within 15 to 20 minutes versus the normal 60 to 120 minutes. This proprietary technology also eliminates the undesired taste of cannabinoid edibles. By changing the way active pharmaceutical ingredients (APIs) enter the body, the user can benefit from lower dosages and quicker effects. The bioavailability of the APIs is improved, while side effects are tempered. As a result, this technology promotes far healthier ingestion methods than smoking or vaping.
Recently, the company announced its entry into a licensing agreement with Cannfections Group Inc. This agreement offers Lexaria the ability to provide commercial clients with high quality chocolate edibles. Cannfections is an infused chocolate and gummies contract manufacturer that was recently established by one of Canada’s oldest and most recognized chocolatiers. The owners of Cannfections have 85 years of experience in the chocolate-making industry that will lend to Lexaria’s long-term strategy of partnering with the world’s best to deliver best-in-class products.
Lexaria has developed various products for demonstration, testing and sales, showing wide applicability. These non-psychoactive cannabinoid products have a high-absorption hemp oil formula, are an excellent source of omegas and essential fatty acids and are engineered for physiological performance and recovery. APIs within Lexaria’s products have been shown to reduce anxiety and stress while promoting focus, offsetting pain and inflammation and supporting circulation.
The company’s sports nutrition focus resulted in its Protein Energy Bars, which are a high source of energy, fiber and protein. ViPova™ branded premium teas deliver cannabidiol in several flavors and are high in anti-oxidants. TurboCBD™ hemp oil capsules are formulated with American ginseng and ginkgo biloba for enhanced focus and memory, and reduced stress and fatigue. Mouth-melt tablets are zero-sugar, rapidly dissolve, and combine the antioxidant properties of pterostilbene with hemp oil. Finally, Lexaria’s beverages are sparkling-clear with no hint of hemp oil flavors. With a continued focus on high quality and cutting edge technology, Lexaria is investigating and will continue to pursue additional technologies.
For more information, visit the company’s website at www.LexariaEnergy.com
More from PsychedelicNewsWire
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) PsychedelicNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…
The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…
Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…
Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…
NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multibillion-dollar unmet needs in central…
Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of…